Trial Profile
Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV (Velaglucerase Alfa)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Velaglucerase alfa (Primary)
- Indications Gaucher's disease type I
- Focus Therapeutic Use
- Acronyms EIROS
- 16 Jun 2021 Status changed from recruiting to completed.
- 09 Nov 2017 New trial record